Flulaval Quadrivalent is a quadrivalent, split-virion, inactivated influenza virus vaccine prepared from virus propagated in the allantoic cavity of embryonated hens’ eggs. Each of the influenza viruses is produced and purified separately. The virus is inactivated with ultraviolet light treatment followed by formaldehyde treatment, purified by centrifugation, and disrupted with sodium deoxycholate.
Flulaval Quadrivalent contains thimerosal.
Flulaval Quadrivalent has been standardized according to U.S. Public Health Service (USPHS) requirements for the 2019-2020 influenza season and is formulated to contain 60 micrograms (mcg) hemagglutinin (HA) per 0.5-mL dose in the recommended ratio of 15 mcg HA of each of the following 4 influenza virus strains (2 A strains and 2 B strains): A/Brisbane/02/2018 (H1N1) pdm09 (IVR-190), A/Kansas/14/2017 (H3N2) X-327, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
Flulaval Quadrivalent is indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Flulaval Quadrivalent is approved for use in persons aged 6 months and older.
Flulaval Quadrivalent is administered as an intramuscular injection.
The preferred sites for intramuscular injection are the anterolateral thigh for children aged 6 through 11 months and the deltoid muscle of the upper arm for persons aged 12 months and older if muscle mass is adequate.
- 6 months through 8 years: Not previously vaccinated with influenza vaccine: Two doses (0.5-mL each) at least 4 weeks apart
- 6 months through 8 years: Vaccinated with influenza vaccine in a previous season One or 2 doses (0.5-mL each)
- 9 years and older: One 0.5-mL dose